Companies › Gossamer Bio USA
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Seralutinib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor | KIT, PDGFRB, PDGFRA, CSF1R | Phase 3 | Pulmonary Arterial Hypertension | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04816604 | Seralutinib | Phase 2 | Pulmonary Arterial Hypertension | Cardiovascular | Sep 2026 |
| NCT06274801 | Seralutinib | Phase 3 | Pulmonary Arterial Hypertension | Cardiovascular | Dec 2026 |
Cash and short-term investments of $57m on 2026-06-30; operating cash outflow about $158m a year; runway about 4 months at that burn, to Nov 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Mineralys Therapeutics Grace Therapeutics Trust Bio-sonics Liquidia Technologies EVD Pharmacy and Medical Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.